Severe Pulmonary Coccidioidomycosis Treated With Systemic Corticosteroids in an Adolescent Child Authors: Rod Shinozaki, Paul Krogstad, Kristina Adachi, Yonca Bulut Published: 2026 ABSTRACT Coccidioidomycosis (CM) is an emerging public health challenge due to an increasing number of cases in the U.S. Diagnosis may be challenging because of its nonspecific presentation, which may lead to treatment delays. In addition, the optimal management of severe pulmonary CM remains unclear. We present the case of an 18‐year‐old immunocompromised renal transplant recipient with a history of systemic lupus erythematosus who developed acute respiratory distress syndrome (ARDS) secondary to severe pulmonary CM. Following initiation of systemic corticosteroids treatment with standard‐of‐care antifungals, she demonstrated improved clinical response. Severe pulmonary CM may lead to a significant multiorgan inflammatory response in this infection. Our case explores corticosteroid treatment to downregulate this pathophysiologic process and help facilitate clinical resolution of the critical respiratory symptoms and limit morbidity associated with this infection. 1. Introduction Coccidioidomycosis, also known as Valley Fever, is a fungal infection caused by two closely related species, Coccidioides immitis or Coccidioides posadasii. California and Arizona, the two main endemic areas, annually report over 95% of all cases [1]. In 2023, over 21,000 cases were reported more than doubling the incidence compared to the prior 10 years [2]. Coccidioidomycosis presents commonly with flu‐like symptoms (e.g., fever, malaise, and cough), although approximately 60% of individuals are asymptomatic [3]. Rarely, coccidioidal infection may progress to severe pediatric acute respiratory distress syndrome (PARDS) or may disseminate to sites beyond the lung, leading to infections of the musculoskeletal system and central nervous system [4, 5]. Prompt diagnosis and management are essential for this under‐recognized disease. Unfortunately, the progression of severe lung disease sometimes occurs despite antifungal therapy. Corticosteroids have been used as an adjunctive therapy in a small number of cases of severe coccidioidal pneumonia in adults, demonstrating resolving fevers and oxygen saturations within days after initiation [6–8]. To our knowledge, there are no descriptions of corticosteroid therapy in children or adolescents with life‐threatening coccidioidal pneumonia. Here, we present a pediatric case of severe pulmonary coccidioidomycosis treated with corticosteroids, which appeared to aid in their recovery. 2. Case Presentation An 18‐year‐old female with a history of systemic lupus erythematosus (SLE) complicated by chronic kidney disease status post kidney transplantation, bipolar disorder and juvenile glaucoma was admitted with respiratory symptoms of rhinorrhea, dry cough, headache, night sweats for three weeks, and diffuse bone pain at the time of admission. She had watery non‐bloody diarrhea, decreased appetite, and emesis leading to a weight loss of eight pounds over the past month and a half. In the last few days prior to admission, she developed new shortness of breath and numbness in her left hand. A chest X‐ray demonstrated diffuse nodular opacities (Figure 1). She was admitted and vancomycin, ceftriaxone, and levofloxacin were begun. Her cough improved but she continued to have fevers greater than 39 degrees Celsius and developed intermitted oxygen desaturations requiring nasal cannula oxygen. Chest X‐ray showing diffuse miliary and multinodular pattern. As seen in Figure 2, her chest CT scan showed diffuse miliary reticular pulmonary nodules, with a focal area of right lower lobe consolidation which had hypoattenuating areas that may have represented early cystic bronchiectasis. Multiple enlarged mediastinal lymph nodes were also appreciated. A bronchoalveolar lavage (BAL) was obtained, which grew Coccidioides species. Her initial coccidioidomycosis serologies were also weakly positive (ELISA IgM positive but IgG negative, and Coccidioides TP Ab indeterminant. A (1, 3)‐Beta‐D‐Glucan (Fungitell) assay was strongly positive (> 500 pg/mL). Oral fluconazole 400 mg BID was begun as empiric therapy for coccidioidomycosis. Interestingly, other serologies also returned positive including Chlamydophila pneumoniae IgG and IgM 1:40, 1:128, Chlamydia psittaci IgG and IgM negative, Chlamydia trachomatis IgM 1:80 positive, IgG negative, and she received a 2‐week course of levofloxacin. Diffuse miliary reticular pulmonary nodules, with a focal area of right lower lobe consolidation that represents diffuse fungal infection. On hospital Day 5, her respiratory distress worsened, with oxygen requirements increasing from the nasal cannula to HFNC 20 LPM 50%–60% FiO2. Her mental status worsened with hallucinations, prompting transfer to the PICU. Her antifungal regimen was escalated to L‐AMB (5 mg/kg daily). Given complaints of intermittent headaches, a lumbar puncture was performed, showing normal opening pressure; CSF studies revealed normal, cell count, protein, glucose, and Coccidioides CF titer and no growth on fungal culture. To evaluate for other occult sites of infection, a bone scintigraphy study was performed (Figure 3), showing increased tracer accumulation in both feet (left greater than right) and the left ankle, thought to be due to Coccidioides involvement along with nonspecific diffuse mild tracer activity observed on the calvarium and orbital bones. Given worsening clinical symptoms including headache, neck stiffness, vomiting, and fevers, fluconazole was restarted and L‐AMB stopped due to poor tolerance symptomatically. Prompted by worsening pain in her extremities a week later, an MRI of her upper and lower extremities was performed and demonstrated marrow edema at multiple locations and joint effusion, compatible with acute osteomyelitis and septic arthritis. Her fluconazole dose was increased further (12 mg/kg/day divided BID), and L‐AMB was restarted following increased respiratory secretions, oxygen requirements of HFNC 15‐20 LPM with FiO2 30%–40% to maintain oxygen saturations above 90%, and worsening pain in her extremities with concern for progression of her infection. In view of this hypoxia, prednisone was increased from her baseline 10 mg daily immunosuppression to previously referenced regimen of prednisone 40 mg orally twice‐daily (BID) for 5 days, 40 mg once‐daily (OD) for 5 days, and then 20 mg OD for 11 days [9]. Within 10 days, her respiratory status improved, and she was able to wean from oxygen support. Increased tracer activity in both feet and left ankle (left greater than right) is thought to be due to injury with osseous CM involvement. Diffuse tracer uptake observed on the calvarium and orbital bones was nonspecific. Two weeks after completing this tapering corticosteroid regimen, a repeat MRI showed an infiltrative lesion of her left upper extremity bone marrow as well as her left foot also in the setting of increasing serum AST and ALT transaminases and GGT elevation while on high‐dose fluconazole. She was switched to posaconazole for fluconazole‐refractory disease and possible fluconazole hepatotoxicity. Her left ulna was biopsied and cultures grew Coccidioides. Sertraline, a selective serotonin reuptake inhibitor often used to treat depression, was added for synergy due to a growing number of studies demonstrating benefit against fungal infections by disrupting protein synthesis and cell wall integrity [10–12] and severity of her disseminated coccidioidomycosis including diffuse radial/ulnar disease. She was eventually discharged after a prolonged 3‐month hospital stay once her respiratory and pain symptoms resolved and her infection was stabilized with long‐term IV infusions of L‐AMB, oral posaconazole, and sertraline. One month after discharge at an ophthalmology clinic appointment, she complained of right eye pain and was noted to have uveitis and prescribed prednisolone acetate drops along with her other glaucoma maintenance medications of timolol, brimonidine, and dorzolamide. Unfortunately, 2 weeks later she returned to the ophthalmology clinic with intense eye pain and markedly decreased vision. She was found to have right partial retinal detachment, macular lesion, vitritis, and poor visualization of the fundus, suspected to be due to endophthalmitis from further dissemination of her coccidioidomycosis in the setting of continued immunosuppression required to treat SLE and prevent rejection of her renal allograft. She was admitted to the hospital for 2 days for close monitoring and management with intravitreal voriconazole. Given poor eye penetration of posaconazole, she was switched to voriconazole, and L‐AMB and sertraline were continued. She had improvement of her pain and vision with repeat intravitreal voriconazole injections as an outpatient every 3 days for a total of four doses. She underwent a vitrectomy and repair of her retinal detachment, with vitreous fluid specimens confirming Coccidioides infection by antigen enzyme immunoassay (EIA) (negative broad‐range fungal PCR and fungal cultures). CSF studies and echocardiogram revealed no signs of cardiac or central nervous system involvement. She did well with the procedure, and 2 weeks later at her follow‐up appointments in the clinic with ophthalmology and infectious disease, she was symptom‐free while continuing on her prolonged Coccidioides treatment with oral voriconazole, L‐AMB, and sertraline. 3. Discussion Primary pulmonary coccidioidomycosis has a spectrum of respiratory manifestations. Most individuals are asymptomatic or have mild symptoms such as fever, cough, and malaise. On rare occasions, Coccidioides infection may rapidly progress to ARDS which carries a high mortality rate [9]. Practitioners in California and Arizona must have a high index of suspicion when a patient in these endemic areas presents with hypoxia, hilar adenopathy, and consolidation on chest X‐ray. Antifungal treatment should begin in hospitalized patients while awaiting the results of the diagnostic serological and microbiological tests, including screening for Coccidioides‐specific antibodies by ELISA and confirmatory immunodiffusion or complement fixation testing [2]. The Infectious Disease Society of America (IDSA) recommends starting with the triazole medications fluconazole or itraconazole if there are signs of extrapulmonary soft tissue or chronic cavitary coccidioidal pneumonia. Special considerations should be taken with fluconazole in renal dysfunction, and one may consider using itraconazole or another triazole medication. If the patient presents with severe ARDS or signs of extrapulmonary dissemination, administering a polyene antifungal (e.g., liposomal amphotericin B) is recommended [13]. Echinocandin antifungal medications are not recommended in the treatment of coccidioidomycosis due to a lack of proven efficacy. As recently reviewed, there is evidence that severe Coccidioides infections may be associated with maladaptive immune system responses dominated by Th2 CD4+ T cells, resulting in the production of IL‐4, IL‐13, and IL‐5 [6]. These Th2 cytokines alter antibody responses and blunt effective Th1 cellular immune responses that are involved in recovery from coccidioidal infection. Several reports in adults have described apparent improvement when corticosteroids are added to antifungal treatment of severe coccidioidomycosis [6, 9]. Exacerbation of pulmonary disease by aberrant immune responses and improvement with anti‐inflammatory therapy is not unique to coccidioidomycosis. For example, corticosteroid therapy has been shown to reduce the need for mechanical ventilation and mortality of adults with Pneumocystis jirovecii [14]. Corticosteroid therapy has also been shown to reduce morbidity and mortality in children with “paradoxical responses” that sometimes occur soon after treatment for pulmonary tuberculosis [15]. Moreover, in severe pulmonary disease associated with SARS‐CoV‐2 (COVID‐19), prevention and treatment of pulmonary inflammation with dexamethasone and other agents is currently being seen as an approach to quell unbalanced and deleterious immune responses triggered by the virus [16, 17]. Short course corticosteroid treatment in coccidioidal infections does not appear to cause adverse events or complications [7, 8]. A short course of steroids for 21 days or less appears to be beneficial and reduce complications from prolonged immunosuppression [18]. It is important to note that those with solid organ transplants and chronic inflammatory conditions being treated with immunomodulators are at higher risk for coccidioidomycosis infections as well as disseminated and more severe infections [19, 20]. Thus, initiating corticosteroids should not be taken lightly. Our patient’s case, which had a history of a kidney transplant and on was chronic immunosuppression complicated by Coccidioides endophthalmitis, highlights these challenges. Given the limited published clinical data or trials regarding the use of corticosteroids in severe pulmonary coccidioidomycosis, we hope this case will stimulate further investigation of their potential utility in the management of severe pulmonary coccidioidomycosis [6, 9]. Funding No funding was received for the production of this manuscript. Ethics Statement Ethical approval was provided for the publication of this manuscript. Consent Written consent was obtained. Conflicts of Interest The authors declare no conflicts of interest.